SCHEMBL3856057

SCHEMBL3856057

CCC(CC)(c1ccc(O)c(C)c1)c1cc2cc(OCc3ccccc3)ccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.50
CASP3 P42574 2/20 0.44
SENP8 Q96LD8 2/20 0.44
SENP7 Q9BQF6 2/20 0.44
SENP6 Q9GZR1 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
PKM P14618 1/20 0.44
ESR2 Q92731 2/20 0.43
AR P10275 1/20 0.43
MAOB P27338 9/20 0.42
NPC1 O15118 2/20 0.42
MAOA P21397 2/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
ALOX5 P09917 1/20 0.41
ACHE P22303 1/20 0.40
MEN1 O00255 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3850788 0.92 MAOB (0.50) ESR1CASP3SENP8SENP7SENP6
SCHEMBL3850401 0.82 VDR (0.55) CASP3SENP8SENP7SENP6AR
SCHEMBL15059762 0.81 ESR1 (0.61) ESR1L3MBTL1ESR2ARMAOB
SCHEMBL3858580 0.80 ALOX5 (0.49) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL3858489 0.78 ESR1 (0.51) ESR1ESR2ARCA12CA1
SCHEMBL13741489 0.76 ESR1 (0.49) ESR1ESR2ARMAOBMAOA
SCHEMBL1437457 0.75 MAOB (0.60) ESR1CASP3SENP8SENP7SENP6
SCHEMBL3852833 0.75 VDR (0.55) ARMAOBMAOAACHE
SCHEMBL5970901 0.74 CASP3 (0.41) ESR1CASP3SENP8SENP7SENP6
SCHEMBL2972327 0.74 ESR1 (0.59) ESR1ESR2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579488-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-08-25 US disclosed
US-7579488-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-08-25 US disclosed
US-7579488-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-08-25 US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
EP-1687289-A1 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-08-09 EP disclosed
WO-2005051938-A1 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070106095-A1 Vitamin d receptor modulators VDR, CYP2R1, CYP24A1 ESR1 174/4885CASP3 798/4885SENP8 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.